Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0500 (1.41%) ($4.9500 - $5.0500) on Wed. May. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.07% (three month average) | RSI | 53 | Latest Price | $5.0500(1.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -0.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TLT(58%) ACES(28%) TAN(19%) IWC(14%) MCHI(12%) | Factors Impacting ADMS price | ADMS will decline at least -2.035% in a week (0% probabilities). GLD(-45%) XLE(-40%) USO(-37%) IVE(-25%) XAR(-24%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.035% (StdDev 4.07%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.21 | 5 Day Moving Average | $5.12(-1.37%) | 10 Day Moving Average | $5.07(-0.39%) | 20 Day Moving Average | $5.21(-3.07%) | To recent high | -14% | To recent low | 0.8% | Market Cap | $143m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |